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Purpose: The transcriptional regulator, nuclear factor-kappa B (NF-κB)/Rel family are involved in neuronal cell death
and survival. Previously, we reported that NF-κBp50-deficient (p50-deficient) mice exhibit many features resembling
human normal tension glaucoma (NTG). The developmental mechanism of human NTG is not clearly understood, and a
radical curative treatment has yet to be established. Our aim is to elucidate the signal cascade which mediates the
spontaneous optic neuropathy in p50-deficient mice as a model of NTG.
Methods: To demonstrate the expression and activation of pro-apoptotic factors, which mediate the death of retinal
ganglion cells (RGCs) in p50-deficient mice, western blot (WB) and luciferase reporter assays with retinas from p50-
deficient and wild type mice, and cultured RGC-5 cells were performed. Furthermore, we tested the neuroprotective effects
of chemical reagents (memantine, lomerizine, and tacrolimus) against N-methyl-D-aspartate (NMDA)-susceptible RGC
damage according to in vitro experiments with RGC-5 cells. To elucidate the NF-κB-mediated death signaling, the effects
of chemical reagents on spontaneous optic neuropathy were examined by histopathological studies.
Results: WB experiments and luciferase reporter assays showed that NF-κB-inducible BCL2-associated X protein (Bax)
and a pro-apoptotic factor, activated caspase 3 were expressed in the retina of p50-deficient mice as well as NMDA-treated
RGC-5 cells. Further, the constitutivelyactivecleaved forms of calcineurin (CaN), which havebeen reported to lead to
apoptosis, were detected in the retina of p50-deficient mice as well as NMDA-treated RGC-5 cells. Pre-treatment with
tacrolimus markedlyprotected RGC-5 cells from NMDA-induced neurotoxicity, and then both spontaneous RGC death
and degenerative changes to the optic nerve in p50-deficient mice were significantlyreduced by the chronic administration
of tacrolimus. The experiments with cultured RGC-5 cells supported the results of histological examinations with p50-
deficient mice, suggesting that CaN activation leads to NF-κB-induced Bax activation and caspase 3 activation, and
mediates spontaneous optic neuropathy in p50-deficient mice.
Conclusions: Research findings show that the chronic administration of tacrolimus significantly reduces spontaneous
optic neuropathy in p50-deficient mice. We demonstrated a potential CaN signal cascade, which spontaneously induces
age-dependent RGC death and degenerative optic nerve changes in p50-deficient mice.
Glaucoma, one of the most common causes of visual
impairment worldwide, is characterized by the apoptosis of
retinal  ganglion  cells  (RGCs)  [1].  Although  increased
intraocular  pressure  (IOP)  has  long  been  considered  the
primary cause of the cell death, evidence from studies on
normal tension glaucoma (NTG) suggests other factors to be
involved in the apoptosis of RGCs, which is induced by a
potential neurotoxic role for glutamate, genetic background,
and autoimmunity [2-4]. Although most anti-glaucomatous
reagents are used to lower IOP, in some cases, the patient's
condition deteriorates in spite of an IOP within the normal
range. Identifying factors, which are quite independent of
IOP, would be necessary to understand the pathogenesis of
glaucoma and guide efforts toward improved therapeutics.
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Nuclear  factor-kappa  B  (NF-κB),  which  acts  as  a
transcription factor, plays a key role in cell survival or the
death signaling pathway, acute central nervous system (CNS)
trauma, and chronic neurodegenerative disorders [5,6].The
NF-κB family, whichis mainlycomposed of p50/p65(RelA)
heterodimers, is found in almost all animal cell types, and is
involved in cellular responses to stimuli such as stress and
cytokines [7]. In unstimulated cells, NF-κB is sequestered to
the cytoplasm by a family of inhibitors called IκBs. With the
degradation of IκB inhibitor, the NF-κB is then free to enter
the nucleus, where it can turn on the expression of specific
genes. Recent reports suggest that the binding site of the
heterodimer  p50-p65  could  also  be  occupied  by  the
homodimer p50-p50, whereupon p50-p50 may function as a
repressor to regulate p50-p65's role as a transcription factor
essential for neuronal response [7]. Impaired regulation of
NF-κB has been linked to various diseases, such as cancer,
inflammatory disorders, and autoimmune diseases, and has
also been implicated in the processes of synaptic plasticity and
memory [8]. In the CNS, it has been reported that the activated
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2157NF-κBp65(RelA)  may  participate  in  glutamate-induced
neurotoxicity,  N-methyl-D-aspartate  (NMDA)-induced
retinal neuronal cell death,retinal ischemia, and reperfusion
injury [9-12]. However, the precise role of NF-κB in cell death
within the CNS is controversial.
In many types of neuron, this excitotoxicity appears to be
mediated  predominantly  by  signaling  pathways,  including
Ca2+ influx through the NMDA receptor, a subtype of the
glutamate receptor [13]. For these reasons, it is likely that
NMDA antagonists, memantine, dizocilpine (MK-801), and
Ca2+  channel  blockers,  such  as  flunarizine,  verapamil,
nicardipine, and lomerizine, prevent retinal damage caused by
NMDA  [14-16].  Calcineurin  (CaN)  is  a  Ca2+-calmodulin-
dependent  phosphatase  highly  expressed  in  the  CNS  and
retina  [17,18].  Activation  of  CaN  leads  to  apoptosis  of
cultured neurons [19]. Tacrolimus, a CaN inhibitor, exhibits
a neuroprotective effect in a wide range of models of acute
apoptotic neuronal death in the CNS, trauma,and stroke [20,
21]. In the retina, tacrolimus has been reported to confer
neuroprotection on RGCs after optic nerve crush [22]. In
addition,  an  increased  IOPis  associated  with  the  CaN-
mediated mitochondrial apoptotic pathway [23]. Furthermore,
tacrolimus  has  been  shown  to  inhibit  glutamate-induced
apoptosis  in  cultured  RGCs  [24].  Although  the
neuroprotective effects of these chemical reagents have been
examined in transient studies employing glaucoma models, it
has yet to be demonstrated whether the chronic administration
of chemical reagents to NTG-animal models has protective
effects against neuropathy.
Previously, we reported that NF-κBp50-deficient (p50-
deficient)  mice  exhibit  a  spontaneous  loss  of  RGCs
independent of IOP, characteristic excavation of the optic
nerve head, and degenerative changes to the optic nerve, with
manyfeatures resembling human NTG [25]. However, the
precise mechanism involved is still unknown. In this study,
we tried to identify the death signaling cascade in the initiation
of spontaneous optic neuropathy in p50-deficient mice as a
model  of  NTG.  The  experiments  demonstrated
neuroprotective  effects  of  several  chemical  reagents,
especially tacrolimus, against NMDA-induced neurotoxicity
and spontaneous RGC death in p50-deficient mice. The defect
in the p50/p50 homodimer, which functions as a repressor to
regulate p50-p65's role, results in optic neuropathy via a CaN
signal cascade involving impaired NF-κB activation in p50-
deficient mice.
We provide a new insight into the role of NF-κBp50 in
the  pathophysiologyof  optic  neuropathy,  and  present
experiments involving p50-deficient mice demonstrating the
CaN-signaling  molecules  including  NF-κB,  suggesting
targets  for  the  development  of  therapeutic  reagents.  Our
research  findings  mayprovide  new  targets  for  therapeutic
intervention in human NTG.
METHODS
Animals: We purchased mice homozygous for the Nfkb1tmBal
target mutation, which have a B6/129-F2 genetic background,
from Jackson Laboratories (Bar Harbor, ME), and C57BL/6J
mice from CLEAJapan, Inc. (Tokyo, Japan). All wild type,
homozygous mice deficient in p50 were littermates of F8
heterozygous mice generated by backcrossing with C57BL/
6J mice. All animal-related procedures were performed in
compliance with the National Institute of Health Guide for the
Care and Use of LaboratoryAnimals and theARVO Statement
for the Use ofAnimals in Ophthalmic and Vision Research.
These mice were kept in a specific pathogen-free environment
at Shinshu University's animal facilities, in accordance with
institutional guidelines (approval no. 03–28–008). A total of
280 mice (wild type mice; n=90, p50-deficient mice; n=190,
at 3 weeks to 10 months of age) were used in this study.
Labeling and counting in RGCs: Retrograde labeling was
performed as reported [25]. Mice were anesthetized by the
intraperitoneal  administration  of  Nembutal  (50  mg/kg;
Dainippon Sumitomo Pharma, Osaka, Japan). The animals
were placed in a stereotaxic apparatus (Narishige, Tokyo,
Japan) and the scalp was incised at the midline and retracted
laterally to make a burr hole at an appropriate location (2.0 mm
posterior  to  the  bregma,  1.2  mm  left  of  the  midline)
determined according to the mouse brain map. A window was
drilled in the scalp, the neurotracer dye Fluoro-Gold (a 4%
solution in saline; Fluorochrome, Denver, CO) was applied
(1 μl at a rate of 0.5 μl/min in each hemisphere) using a
Hamilton syringe, and the skin over the wound was sutured.
Five days after the application of Fluoro-Gold, mice were
euthanized and, after their eyes were enucleated, the retinas
were  detached  as  flattened  whole  mounts  in  4%
paraformaldehyde in PBS. Labeled cells from 10 fields of
identical  size  (230×150  μm)  were  counted  under  a
fluorescence microscope. The counted fields were located at
approximately  the  same  distance  from  the  orra  serata
(500 μm). Fields were counted by 2 blinded observers, and the
average number of RGCs per field was calculated for each
retina and analyzed by ANOVA with Bonferroni correction.
Immunohistochemistry (IHC) and immunofluorescence: The
retinas of mice ranging in age from 3 weeks to 10 months were
used for research experiments. Mice were euthanatized and
their  eyes  were  immediately  enucleated  and  fixed  (4%
paraformaldehyde). Paraffin-embedded retinas were used for
IHC  and  immuno-fluorescence  experiments.  The  sections
were  dewaxed  and  rinsed  with  phosphate-buffered  saline
(PBS). Then, they were incubated with 10% BSA (BSA) for
120 min at room temperature. After rinsing with PBS, the
sections  were  incubated  with  primary  antibodies,  rabbit
polyclonal antibodyto p65 (1:200, Santa Cruz Biotechnology,
CA), anti-caspase 3 rabbit polyclonal antibody (1:100; EMD
Bioscience, Darmstadt, Germany), and Bax 6A7 monoclonal
antibody (1:200; TREVIGEN, Gaithersburg, MD), overnight
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negative  control.  After  a  wash  with  PBS,  the
secondaryantibody, Alexa Fluor 488-conjugated donkey anti-
rabbit IgG (1:200, Invitrogen Corp., Carlsbad, CA), Alexa
Fluor  546-conjugated  goat  anti-rabbit  antibody  (1:200;
Invitrogen),  and  Alexa  fleur  488  conjugated  mouse  IgG1
antibody  (1:200;  Invitrogen)  were  reacted  at  room
temperature for 2 h. Finally, the sections were coverslipped
with  antifade  mounting  medium  (VECTASHILD;  Vector
Laboratory, Inc., Burlingame, CA). Sections were examined
under a Leica laser scanning confocal microscope (TCS SP2
AOBS; Leica Microsystems GmbH, Wetzlar, Germany). For
in  situ  TdT-mediated  dUTP  nick-end  labeling  (TUNEL)
assays, paraffin-embedded retinas were used. The sections
were dewaxed and rinsed with PBS. The TUNEL assay was
performed  using  Apop  Tag  Fluorescein  In  situ  Apoptosis
Detection Kit according to the manufacturer's instructions
(MILLIPORE, Billerica, MA). After labeling, the slides were
mounted with mounting medium (VECTASHIELD; Vector
Laboratories) for fluorescence microscopy with PI nuclear
staining.
Western blot: The retinas were dissected from mouse eyes
derived  from  wild  type  and  p50-deficient  mice,  and
homogenized in modified RIPA buffer (50 mM Tris [pH7.4];
1% NP-40; 0.25% Na-deoxycholic acid; 150 mM NaCl; 1 mM
EDTA;  1  mM  NaF;  1  mM  PMSF;  1  mM  Na3VO4;  and
aprotinin, leupeptin, pepsatain at 1 μg/ml each). The samples
were heated at 95 °C for 10 min and centrifuged at 20,000× g
for 20 min, and the supernatants were stored as retinal crude
extracts at −30 °C. These extracts (10 μg) were run on a 10%
SDS–PAGE, and an immunoblot analysis was performed with
a rabbit monoclonal antibody to NF-κBp50 (Epitomics, Inc.,
Burlingame, CA), rabbit polyclonal antibody to NF-κBp65,
rabbit  polyclonal  antibody  to  Calcineurin  (Exalpha
Biologicals Inc., Watertown, MA), rabbit polyclonal antibody
to caspase 3 (EMD Bioscience), rabbit polyclonal antibody to
p-actin (Santa Cruz technology, Inc., Santa Cruz, CA), and
mouse  monoclonal  antibody  to  Bax  (TREVIGEN)  using
standard  procedures.  Immunodetectable  proteins  were
visualized and enhanced using the ECL western blot system
(GE Healthcare Bio-Science, Uppsala, Sweden).
Cytosol and nuclear extracts: Cultures of retinal ganglion
cells (RGC-5, a rat ganglion cell line transformed using the
E1A virus), which were provided by Dr. Neeraj Agarwal
(UNT  Health  Science  Center,  Fort  Worth,  TX),  were
maintained in Dulbecco's modified Eagle's medium (DMEM;
Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine
serum (FBS; Valeant, Costa Mesa, CA), 100 U/ml penicillin
(Meiji Seika Ltd., Tokyo, Japan), and 100 μg/ml streptomycin
(Meiji Seika Ltd., Tokyo, Japan) in a humidified atmosphere
of 95% air and 5% CO2 at 37 °C. The RGC-5 cells were
passaged by trypsinization every 3–4 days. Cytosol extracts
and nuclear extracts were prepared from 1×106 RGC-5 cells.
Cells  were  harvested,  centrifuged  for  10  min  at  130×  g,
washed in 1 ml of ice-cold PBS, and centrifuged for 15 s at
17,000× g in an Eppendorf Brinkman-5412 centrifuge at 4 °C.
Cells were pelleted and washed once in 0.4 ml of buffer A
(10mM Hepes, pH7.8; 10 mM KCl; 2 mM MgCl2 ; 1 mM
dithiothreitol  [DTT];  0.1  mM  EDTA;  0.1  mM
phenylmethylsulfonyl  fluoride  [PMSF];  5  μg/ml  antipain
[Sigma, St Louis, MO], and 5 Ig/ml leupeptin [Sigma]) and
incubated on ice for 15 min. Then, 25 μl of a 10% Nonidet
P-40 solution (Sigma) was added, and cells were vigorously
mixed for 15 s and centrifuged for 30 s at 17,000× g. Pelleted
nuclei were resuspended in 40 μl of buffer C (50 mM Hepes,
pH 7.8; 50 mM KCl; 300 mM NaCl; 0.1 mM EDTA; 1 mM
DTT; and 0.1mM PMSF; 10% [v/v] glycerol), mixed for 20
min, and centrifuged for 5 min at 17,000× g at 4 °C. The
supernatant containing the nuclear proteins was harvested, the
protein concentration was determined, and the samples was
stored at −80 °C.
Cell transfections and reporter assays: RGC-5 cells were
seeded at 70% confluence in 6-well plates, and a total of
2 μg of luciferase reporter vectors (Bax [full] promoter-Luc
and Bax (ΔκB) promoter-Luc), provided by Dr. Chotteau-
Lelievre  (University  of  Sciences  et  Technologies,  Cedex,
France), was transfected into RGC-5 cells with FuGENE6
Transfection  Reagent  according  to  the  manufacturer's
recommendations (Roche Diagnostics, Indianapolis, IN). All
transfections  contained  200  ng  of  pCMV-LacZ  (Roche
Diagnostics) as an internal transfection efficiency control.
Glutamate  (final  concentration,  50  μg)  was  added  to  the
culture medium at 48 h after transfection and the cells were
washed for the preparation of whole cell lysates. Cell lysates
were prepared 24 h later for the assays of luciferase (Promega
Corp.,  Madison,  WI)  and  p-galactosidase  (Galactolight;
Roche  Applied  Science)  activities  followingthe
manufacturer's  instructions  and  using  a  GloMax®20/20
Luminometer  (Promega  Corp.).  The  measured  luciferase
activity  was  corrected  by  using  co-transfected  pCMV-p-
galactosidase activity as an internal control.
N-methyl-D aspartate (NMDA) injection and morphometric
analysis: The intravitreal injection of NMDA was performed
as described previously [25]. A total of 1 μl of 5 or 10 nM
solution of NMDA in PBS was injected into the vitreous of
one  eye.  PBS  alone  was  injected  into  the  other  eye  as  a
negative control. At 24 h after the injection, the eyes were
enucleated and fixed in 4% paraformaldehyde in PBS (Wako,
Tokyo,  Japan),  dehydrated,  and  embedded  in  paraffin.
Transverse sections were made though the optic disc and
stained with hemotoxylin and eosin. The surviving cells of
0.35 mm in length at 0.3 mm from the edge of the optic disc
and orra serata in the ganglion cell layer (GCL) were counted,
except the cells infiltrating the GCL. The average number of
cells per field was analyzed using the Mann–Whitney U test.
Chemical reagents: NMDA receptor antagonists, MK-801
and memantine, were purchased from Sigma-Aldrich Japan
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and a potential anti-migraine drug, lomerizine hydrochloride,
were  supplied  by  Nippon  Organon  (Osaka,  Japan).  The
calcineurin  inhibitor  tacrolimus  was  supplied  by  Astellas
Phama Inc. (Tokyo, Japan). Lomerizine was dissolved in 2%
dimethyl sulfoxide (DMSO) containing 0.2% tartaric acid.
MK-801 and memantine were dissolved with distilled water,
and tacrolimus was dissolved with saline. The p50-deficient
mice and wild-type mice aged 2 months were daily pre-treated
intraperitoneally  with  memantine  (10  mg/kg),  MK-801
(0.5 mg/kg), lomerizine (1 mg/kg), or tacrolimus (2, 0.5 and
0.2 mg/kg) for one week before the NMDA injection (shown
in  Appendix  1-Figure  3).  These  mice  were  given  an
intravitreous injection of 5 nM NMDA, which is a relatively
low concentration for causing neurotoxicity.
Transfection and cell death assay: A total of 2 μg of NF-
κBp50  expression  vector,  provided  by  the  NIH  AIDS
Research  and  Reference  Reagent  Program  (Germantown,
MD),  was  transfected  into  RGC-5  cells  with  FuGENE6
Transfection  Reagent  according  to  the  manufacturer's
recommendations (Roche). All transfections contained 200 ng
of pCMV-LacZ (Roche Diagnostics) as an internal control.
The transfected-cells were cultured with the culture medium
containing  glutamate  (final  concentration,  50  μM)  or  N-
methyl D aspartate (NMDA; final concentration, 50 nM) for
24 h after the transfection and washed for the preparation of
whole cell lysates as well as nuclear and cytosolic extracts.
The  RGC-5  cells  were  pre-treated  with  tacrolimus  (final
concentration, 50 μM or 100 μM) for 24 h, and then glutamate
or  NMDA  was  added  for  24  h.  After  stimulation  with
glutamate or NMDA, RGC-5 cells were treated with Tripsin-
EDTA solution (GIBCO, Grand Island, NY) and scraped from
the plate. Viable cells were counted by trypan blue exclusion.
The average number of live RGC-5 cells was analyzed to
obtain the mean values±SD of live cells.
Oligonucleotides  and  electrophoretic  mobility  shift  assay
(EMSA):  Double-stranded  oligodeoxynucleotides  were
prepared  by  the  phosphoramidate  method  with  a
DNAsynthesizer  and  purified  on  an  OPC  cartridge
(FASMAC, Inc. Kanagawa, Japan). They correspond to wild-
type κB (5′-GAT CTA GGG ACT TTC CGC TGG GGA CTT
TCC AG-3′) binding motifs of the human immunodeficiency
virus type 1 (HIV-1κB) enhancer or the SP1-binding motif
(5′-ATT CGA TCG GGG CGG GGC GAG C-3′). For EMSA,
nuclear extracts were incubated for 30 min at 37 °C in a total
volume of 10 μl containing 10 mM Hepes-NaOH (pH 7.9),
50 mM KCl, 5 mM Tris-HCl (pH 7.0), 1mM DTT, 15 mM
EDTA, 10% glycerol, 1.0 μg of poly (dI'dC), and 4 ng of wild-
type HIV-1κB or SP1 oligonucleotides. The resulting DNA–
protein  complexes  were  resolved  by  electrophoresis  on
nondenaturing 8% polyacrylamide gels with 0.5× Tris borate-
EDTA  buffer  at  4  °C.  NF-κB-binding  activities
wereexamined by EMSA as described [26].
Chronic administration of various chemical reagents: In the
chronic  administration  experiments,  daily  intraperitoneal
injections of lomerizine (1 mg/kg), memantine (10 mg/kg),
tacrolimus (2 mg/kg), or vehicle (PBS) to p50-deficient mice
were initiated from the age of 2 months for 8 months (shown
in Appendix 1-Figure 4). To elucidate the neuroprotective
effects of several chemical reagents, RGC survival in control
mice and mice of all treatment groups was examined by the
retrograde fluorescence labelingof RGCs.
Azan Mallory stain: Mice were euthanized and their eyes were
immediately enucleated and fixed (4% paraformaldehyde).
Paraffin-embedded  retinas  were  used.  The  sections  were
dewaxed  and  rinsed  with  water.  They  were  incubated  in
mordant containing potassium bichromate and trichloroacetic
acid at room temperature for 10 min. After being rinsed with
water, the sections were incubated in Orange G solution in a
moisture chamber for 10 min at 4 °C. Following more rinsing
in water, they were incubated in Azocarmine G solution in the
moisture chamber again for 20 min at 4 °C, rinsed with water,
and  incubated  in  phosphotungustic  acid  and
phosphomolybdic acid solution in the moisture chamber for a
further 10 min at 4 °C. Following further rinsing with water,
the sections were incubated in Aniline Blue solution in the
moisture chamber for a final 15 min at 4 °C. After being rinsed
with water, the sections were incubated using an ascending
alcohol series.
Morphometry and transmission electron microscopy: After
anesthesia, transcardinal perfusion was performed with 4%
paraformaldehyde,  and  the  optic  nerves  were  dissected
starting at 2 mm behind the globe, and placed in fixative
(approximately  20  ml  of  2.0%  glutaraldehyde  and  2.0%
paraformaldehyde in 0.1 M cacodylate buffer) for 12 h. The
optic nerves were then post-fixed in 1% osmium tetroxide,
dehydrated  in  ethanol,  and  embedded  in  EPOK812
(Okenshoji,  Tokyo,  Japan).  For  transmission  electron
microscopy, ultrathin sections were cut perpendicular to the
long axis of the optic nerves on an ultramicrotome, stained
with uranyl acetate and lead citrate, and examined using a
JEM1200EX transmission electron microscope (JEOL, Ltd.,
Tokyo, Japan). For light microscopic observation, toluidine
blue staining was used. The numbers of axons in 10 fields of
identical  size  (18×18  μm)  were  counted  using  Image  J
software (National Institute of Heath, MD), and the average
number of axons was analyzed by ANOVA (ANOVA) with
the Mann–Whitney U test.
RESULTS
Age-dependent spontaneous RGC death due to apoptosis in
NF-κBp50-deficient  mice:  NF-κB,  which  is  expressed  in
RGCs as well as the CNS, plays important roles in such
processes  as  synaptic  activity  and  cell  survival  [6].
Morphometric evaluation indicated that at 5 months, there was
no difference in the thickness and construction of each retinal
layer,  especially  the  inner  nuclear  layer  (INL)  and  outer
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3 weeks, 2 months, 5 months, and 10 months were counted
using  a  retrograde  labeling  method,  and  the  number  at  5
months  and  10  months  of  age  (n=each  8~12  mice)  had
markedly  decreased  compared  with  that  in  wild-type
littermates (Figure 1A).
To demonstrate whether the p50-deficiency affected NF-
κBp65 activation and RGC survival in the retina, we examined
NF-κBp65 expression at 2 months of age. NF-κBp65 was
detected  in  the  cytoplasm  of  RGCs  of  wild-type  mice.
Unexpectedly,  IHC  clearly  showed  that  NF-κBp65
spontaneously  localizes  in  the  nucleus  of  RGCs  in  p50-
deficient mice under normal conditions (Figure 1B); the p50-
deficiency in RGCs may result in the induction of NF-κBp65's
neuronal  toxicity.  Western  blot  (WB)  analysis  strongly
supports the IHC findings (Figure 1B). Bax and Caspase 3,
Figure 1. Activation of pro-apoptosis factors, caspase 3, Bax, and p65(RelA), and calcineurin in the retina of p50-deficient mice. A: Age-
related ganglion cell death in p50-deficient (KO) mice. Retrogradely labeled cells from 10 fields of identical size (230×150 μm) in flat-mounted
retinas were counted under a fluorescence microscope. The fields were located at approximately the same distance from the orra serata (500
μm). Scale bar=100 μm. The average number of RGCs per field was calculated for each retina and analyzed by Bonferroni correction. Data
are the mean±SEM (each 8~12; *p<0.01). B: Immunohistochemical staining for NF-κBp65 expression at 2 months in wild-type (WT) mice
and p50-deficient mice. NF-κBp65 translocates into the nucleus of RGCs in KO mice. GCL=ganglion cell layer, IPL=inner plexiform layer.
Green; p65, Red; PI. Original magnification; 120×. Western blot analysis of NF-κBp65 and Bax protein levels in KO mice and WT mice.
Immunoreactive bands of NF-κBp65 in the nucleus were slightly more intense in KO than WT mice. C: western blot analysis of pro-apoptosis
factors, Bax, caspase 3 and p65(RelA), and calcineurin (CaN) levels in KO mice and WTmice. Bax protein levels were also slightly increased
in KO mice. Activated caspase 3 and cleaved CaN were detected in KO mice. D: The luciferase reporter vectors containing the wild-type or
mutated B sites of the PMBaxSacI bax promoter (−386 to −1) or the corresponding empty luciferase reporter vector (shown in Appendix 1-
Figure 1) were transiently co-transfected with or without the NF-κBp50 expression vector in RGC-5 cells. RGC-5 cells, pre-treated with
tacrolimus, were stimulated by glutamate for the final24 h, and then luciferase activities were measured. Values were normalized to those
obtained with the co-transfected pSV-β-galactosidase expression vector. Each assay was performed at least three times in triplicate. Luciferase-
reporter assays showed that glutamate-treatment markedly induced Bax expression due to NF-κB activation. Data are presented as the mean
for three independent experiments (*S.D.).
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mediates stress-induced RGC death as well as glutamate-
induced  apoptosis  in  cultured  neuronal  cells  [27-29].
Furthermore, Bax is required for the RGC death pathway in
DBA/2J mice, which is an IOP-dependent glaucoma model.
The WB results showed that Bax expression in the retinas of
p50-deficient mice was slightly higher than that in wild-type
mice, and further activated forms of caspase 3 were detected
in  the  retinas  from  p50-deficient  mice  (Figure  1C).  The
constitutively active cleaved form of calcineurin (CaN) has
been  reported  to  lead  to  apoptosis  by  elevating  IOP  in
experimental  glaucoma  [28].  The  WB  results  showed  the
presence of the full-length CaN in all retinas examined, and
that cleaved CaN occurred only in retinas from p50-deficient
mice (Figure 1C).
To  demonstrate  whether  glutamate  treatment  directly
induces  Bax  expression  via  NF-κB  activation,  luciferase
reporter assays using cultured RGC-5 cells were performed.
Although Bax promoter activity was strongly induced in the
experiment using the reporter construct containing the wild-
type B-binding site after glutamate-treatment, the activitywas
not clearly detected using the reporter construct containing the
mutated B-binding site (Figure 1D, Appendix 1-Figure 1).
These results suggested that NF-κB directly recognized the
κB  site  and  positively  regulated  the  Bax  promoter  after
glutamate-treatment (Figure 1D). These findings show that
the p50-deficiency results in a decrease in viable RGCs due
to high levels of Bax expression and caspase 3 activation,
suggesting that RGCs are spontaneously to undergo apoptosis
by a CaN signal cascade in the retina of p50-deficient mice.
The  effects  of  chemical  reagents  on  the  susceptibility  to
NMDA-treatment  in  p50-deficient  mice:  NMDA-receptor-
mediated  excitotoxicity  reportedly  contributes  to
glaucomatous  neuropathy  [12].  Surviving  RGCs  were
counted at 24 h after the intravitreal injection of 10, and 5 nM,
NMDAor vehicle (PBS). The treatment with 5 nM or 10 nM
NMDA for 24 h markedly induced RGC death in the ganglion
cell layer (GCL) in p50-deficient mice, but not in wild-type
mice. Morphometric evaluation demonstrated no significant
difference in the thickness of the inner plexiform layer (IPL)
between the p50-deficient and wild-type mice treated with 5
nM NMDA (Appendix 1-Figure 2A). The IHC experiment
clearly  showed  that  after  NMDA  treatment,  NF-κBp65
translocated to the nucleus in the RGCs of the wild-type as
well as p50-deficient mice (Appendix 1-Figure 2B).
To determine whether Ca2+ signaling molecules mediate
NMDA-induced  neurotoxicity  in  p50-deficient  mice,  we
examined the neuroprotective effects of chemical reagents,
which  act  on  the  Ca2+-signaling  pathway  including  CaN
activation, on NMDA-induced RGC death. The p50-deficient
mice at 2 months of age, showing normal RGC survival,
underwent  intraperitoneal  pretreatments  with  a  NMDA
antagonist,  MK801  or  memantine;  calcium  blocker,
lomerizine; and CaN inhibitor, tacrolimus, daily for 1 week
before the injection of 5 nM NMDA (Appendix 1-Figure 3).
Histological  examination  of  the  retinas  at  24  h  after  the
intravitreal injection of NMDAshowed protective effects of
the chemical reagents against NMDA-induced neurotoxicity
(Appendix 1-Figure 4A). Morphometric evaluation indicated
marked NMDA-induced neurotoxicity in p50-deficient mice
(12.3* 7.2 cells, n=12) in contrast to wild-type mice (17.9*
8.9 cells, n=10). The pre-treatments with chemical reagents
markedly  protected  RGCs  from  NMDA-induced
neurotoxicity (Appendix 1-Figure 4B).
In addition, RGCs were protected from NMDA-induced
neurotoxicity on pre-treatment with tacrolimus at the various
concentrations indicated in Appendix 1-Figure 4C. The retinal
damage was reduced compared with that in mice treated with
NMDAalone, even following the systemic injection of a low
dose of tacrolimus.
Glutamate-induced RGC apoptosis via calcineurin signal
cascade including impaired NF-κB activation: To verify the
key role of NF-κBp50 and protective effect of tacrolimus
against  glutamate/NMDA-induced  neurotoxicity,  in  vitro
experiments using cultured RGC-5 cell lines were performed.
Glutamate/NMDA-induced  neurotoxicity  was  clearly
observed in a dose-dependent manner (Figure 2A). First, p50-
overexpression  markedly  protected  RGC-5  cells  from
glutamate/NMDA-induced  neurotoxicity  (Figure  2A).  A
quantitative assessment of the protective effects of tacrolimus
is shown in Figure 2A. To demonstrate the biologic effect of
p50-overexpression or pre-treatment with tacrolimus on NF-
κB  expression  under  glutamate-  neurotoxicity,  the
localization  of  NF-κBp65  and  p50  in  RGC-5  cells  after
glutamate-stimulation was examined. WB analysis showed
that glutamate markedly induced the expression and nuclear
translocation  of  NF-κB  (p65/p50  heterodimer;  Figure  2B,
lanes 1, 3, 5, and 7). In the case of p50-overexpression, NF-
κBp50  was  significantly  detected  in  the  nucleus  without
glutamate, and then nuclear NF-κBp50 expression markedly
increased after the stimulation (Figure 2B, lanes 2, 4, 6, and
8). Experiments with EMSA revealed that after stimulation
with  glutamate,  NF-κBp50  expression  resulted  in  a  large
number of p50 homodimer complexes and a slight decrease
in p65/p50 heterodimer complexes in comparison with the
none  transfected-cells  (Figure  2C).  Although  Bax  was
strongly  expressed  after  glutamate  treatment,  p50-
overexpression  reduced  the  glutamate-induced  Bax
expression (Figure 2C, lanes 9, 10, 11, and 12). Luciferase-
reporter assays supported the WB results, suggesting that p50-
overexpression  significantly  prevented  glutamate-induced
Bax expression (Figure 2C). It is possible that the binding site
of the heterodimer p50-p65 could also be occupied by the
homodimer p50-p50, whereupon p50-p50 may function as a
repressor to regulate p50-p65's role as a transcription factor
essential for neuronal response [30,31] (Appendix 1-Figure
6).
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2162Figure 2. Systematic neuroprotection by systemic application of tacrolimus or p50 expression in cultured RGC-5 cells. A: Quantitative
assessment of the protective effects of p50 expression and tacrolimus against NMDA- or glutamate-induced neurotoxicity. Cell viability was
markedly decreased by the application of glutamate or NMDA. Neuroprotective effects of p50 expression or tacrolimus were observed. B:
western blot analysis indicates the effects of p50 overexpression or tacrolimus (Tac.) pre-treatment on NF-κBp65 and p50 expression in RGC-5
cells after glutamate treatment; nucleus (Nuc.) and cytosol (Cyt.). C: Electrophoretic mobility shift assay (EMSA) demonstrates the effects
of p50 overexpression or tacrolimus pre-treatment on NF-κB (p65/p50) activation before and after glutammate treatment. Nuclear extracts
were incubated with a double-stranded oligonucleotide spanning the two B binding sites within the murine bax promoter (B sites). The arrows
indicate the position of the protein-DNAcomplexes. Each lane contains the B sites probe (P) without (lane 1) or with the nuclear extracts
prepared from control cells (C) RGC-5 cells (lane 2 and 5), RGC-5 cells transfected with the p50 expression vector (lane 3 and lane 6), and
RGC-5 cells pre-treated with tacrolimus (Tac.; lane 4 and lane 7). Western blot analysis using whole cell extracts also indicates Bax levels
under the culture conditions with p50 overexpression (left panel, lane 10, 12) or tacrolimus pre-treatment (right panel, lane 10, 12). D: The
luciferase reporter vectors containing the wild-type or mutated B fragments of the PMBaxSacI bax promoter (−386 to −1) or the corresponding
emptyluciferase reporter vector (shown in Appendix 1-Figure 1) were transiently co-transfected with or without the NF-κBp50 expression
vector into RGC-5 cells. RGC-5 cells were pre-treated with tacrolimus for 24 h at 48 h after transfections with the luciferase reporter vectors.
Following pre-treatment with tacrolimus, RGC-5 cells were stimulated by glutamate for 24 h, and then luciferase activities were measured.
Values were normalized to those obtained with the co-transfected pSV-β-galactosidase expression vector. Each assay was performed at least
three times in triplicate. Data are presented as the mean for three independent experiments (*S.D.). E: western blot analysis indicates the
effects of p50 overexpression or tacrolimus (Tac.) pre-treatment on caspase 3 and calcineurin (CaN) activations in RGC-5 cells after glutamate
treatment. Although the glutamate treatment activated caspase 3 and cleaved CaN, p50 overexpression resulted in a decrease in both active
caspase 3 and cleaved CaN expression in RGC-5 cells after glutamate treatment. The pre-treatment with tacrolimus completely inhibited the
glutamate-induced activation of calcineurin, and slightly decreased the level of activated caspase 3.
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2163Figure 3. Neuroprotection by various chemical reagents in p50-deficient mice. A: Bar graph shows RGC survival at 8 months old p50-deficient
(KO) and wild-type (WT) mice. Values represent the mean *±SD (n=each 5 11). RGC numbers of KO mice were significantly decreased
(**p<0.0001). However, the chronic administration of lomerizine or tacrolimus to KO mice for 6 months resulted in an increase in surviving
RGC numbers (**p<0.0001). The chronic administration of memantine to KO mice for 6 months mildly protects RGCs from neurotoxity
(p=0.015). The number of surviving RGCs was counted using retrograde labeling methods. Data was analyzed by Bonferroni correction. B:
Photographs show a high-power view of retrograde-labeled RGCs of flat mounts derived from KO and WTmice at 8 months of age. Scale
bar=100 μm. C: TUNEL staining using the Apop Tag fluorescein labeled kit (Millipore) plus tissue sections from 2-month-old wild type (WT)
mice and p50-deficient (KO) mice, and 10-month-old wild type (WT) mice and KO mice with and without chronic administration of tacrolimus.
TUNEL staining was observed in the GCL of 10-month-old KO mice, but not age-matched KO mice treated with tacrolimus (Tac.) or WT
mice.
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2164Glutamate  did  not  markedly  induce  NF-κBp50
expression in the cytosol or nucleus on pre-treatment with
tacrolimus (Figure 2B, lanes 2, 4, 6, and 8). The pre-treatment
with tacrolimus reduced the glutamate-induced translocation
of NF-κB (p65/p50) from the cytosol to nucleus in RGC-5
cells (Figure 2B, lanes 7 and 8); the results obtained by EMSA
strongly supported the WB results (Figure 2C). Glutamate-
induced Bax expression was weakly observed in the cultures
pre-treated with tacrolimus. Luciferase-reporter assays using
Bax  (full)  promoter-Luc  and  Bax  (ΔκB)  promoter-Luc
(Appendix 1-Figure 1) supported the WB results, suggesting
the prevention of glutamate-induced Bax expression by pre-
treatment with tacrolimus (Figure 2D). Although activated
caspase 3 was clearly detected in RGC-5 cells after glutamate
treatment, the overexpression of p50 or pre-treatment with
tacrolimus resulted in a reduction in activated caspase 3 levels
in glutamate-stimulated RGC-5 cells (Figure 3E). Cleaved
CaN was observed in RGC-5 cells overexpressing p50 and
control  RGC-5  cells  after  glutamate  treatment,  and  pre-
treatment  with  tacrolimus  inhibited  CaN  activation  in  the
glutamate-stimulated RGC-5 cells (Figure 3E). As a result,
the neuroprotective effect of pre-treatment with tacrolimus on
glutamate-induced  neurotoxicity  is  attributed  to  the
prevention of CaN-induced NF-κB expression.
The  neuroprotective  effect  of  chronic  administration  of
chemical reagents: In the present study, we investigated the
age-related  survival  of  RGCs  in  p50-deficient  mice,  and
whether the chronic administration of tacrolimus prevents the
development of spontaneous optic neuropathy. We examined
the neuroprotective effect of the chronic administration of
chemical reagents on the development of spontaneous optic
neuropathy. The intraperitoneal application of tacrolimus, and
additional  reagents,  memantine  and  lomerizine,  which
reportedly have neuroprotective effects, daily for 8 months to
p50-deficient mice was performed, and then the surviving
RGCs were counted usingretrograde labeling (Appendix 1-
Figure 5). The p50-deficient mice treated without the chronic
administration exhibited a significant age-related decline in
RGC numbers for 10 months compared with wild-type mice
(Figure 3A). The p50-deficient mice treated with chemical
reagents  showed  the  following  RGC  counts:  memantine:
69.1* 23.8 (n=9), lomerizine: 74.6* 19.4 (n=5), tacrolimus:
75.4* 18.6 (n=5; Figure 3A). Statistical analysis of the cell
counts of dye-filled RGCs in flat-mounted retinas revealed
significant  differences  between  the  treatments  with  and
without  chemical  reagents,  tacrolimus,  memantine,  and
lomerizine (Figure 3B). The appearance of TUNEL-positive
RGCs of p50-deficient mice was markedly decreased by the
chronic administration of tacrolimus (Figure 3C). These in
vivo experiments provided strong evidence supporting our
hypothesis  regarding  the  protective  effects  of  the  chronic
administration of chemical reagents, especially tacrolimus,
against age-dependent spontaneous RGC death.
The clear excavation of the optic nerve head is observed
at 10 months of age in p50-deficient mice [25]. Importantly,
in  the  case  of  chemical  reagent-treated  mice,  histological
abnormalities of the optic nerve head were not detected in any
mice  examined  (memantine:  n=9,  lomerizine:  n=5,
tacrolimus: n=5; Figure 4A). As shown in the azan staining
experiments, although an increase in collagenous fibers (blue
staining) caused by axonal loss was clearly detected in the
optic  nerve  sections  of  p50-deficient  mice,  the  chronic
administration  of  tacrolimus  markedly  suppressed
collagenous  fibers  (Figure  4B,  upper  panel).  Electron
microscopic analysis of a cross-sectioned optic nerve revealed
that  the  area  of  each  axon  at  8  months  of  age  expanded
considerably more in p50-deficient mice than age-matched
wild-type mice, in association with a decrease in the number
of axons (Figure 4B, lower panel). However, on the chronic
administration of tacrolimus, neither a decrease in the number
of axons nor an increase in the area of connective tissue
surrounding the axons was seen (Figure 4B, lower panel).
Although the number of axons significantly decreased in p50-
deficient mice compared to age-matched wild type mice, it did
not decrease in the mice treated with tacrolimus (Figure 4C,
n=each 5). The chronic administration of chemical reagents,
especially tacrolimus, effectively protected not only RGCs but
also  the  optic  nerve  from  spontaneous  neuropathy.  The
amount of Bax in RGCs of p50-deficient mice was markedly
decreased by the chronic administration of tacrolimus (Figure
4D).
DISCUSSION
NTG shows chronic optic neuropathy and results in a loss of
the  visual  field  independently  of  IOP.  Several  population
studies have suggested that NTG represents 20%–90% of all
primary open angle glaucoma, with percentages seeming to
vary according to race [32]. Factors, quite independent of IOP,
may contribute to disease progression and recent studies have
shown  that  glaucoma  is  affected  by  multiple  genetic  and
environmental factors [33,34]. It should be noted that many
NTG patients continue to suffer visual field loss in spite of a
sufficient  reduction  in  IOP.  It  is  therefore  important  to
understand the pathogenesis of NTG and establish methods of
treatment.
Studies of postmortem brain tissues from patients with
neurodegenerative disorders such as Alzheimer or Parkinson
disease revealed increased NF-κB activity closely associated
with  the  neurodegenerative  process.  NF-κB  reportedly
regulates apoptosis in response to stress in the nervous system,
in addition to regulating apoptosis in a large variety of cells
and tissues. It is difficult to perform analyses using human
materials, and so animal studies complement human studies
and provide important insights into human NTG. Although
glutamate transporter-deficient mice also exhibit spontaneous
RGC death and optic nerve degeneration without an increase
in IOP, the mice don't show symptoms of chronic ailments
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2165Figure 4. The histopathological changes and decrease in Bax expression in p50-deficient (O) mice with chronic administration of tacrolimus:
A: Light micrographs of cross sections derived from the un-treated wild type (WT), and p50-deficient (KO) mice at 10 month of ages, and
the age-matched KO mice treated by chronic administration of tacrolimus, lomerizine or memantine. Although the histopathological results
show obvious excavation of the optic nerve head and RGC loss in the un-treated KO mice, no cupping is observed in the KO mice treated by
chronic administration of tacrolimus, lomerizine or memantine. Serious losses in surviving RGCs are not detected in the KO mice treated with
tacrolimus. Original magnification; (upper panels, low magnification 5×; lower panels, high magnification 20×). B: Azan staining; although
the increase in collagenous fibers (blue color staining) caused by the axonal loss was clearly detected in optic nerve sections of KO mice, the
chronic administration of tacrolimus prevented the increase (upper panel: original magnification; 40×). Electron microscopic examinations
were performed for detection of morphological abnormalities of cross-sectioned optic nerve axons (lower panel). The KO mice exhibit an
expanding area of each axon as well as decreasing number of axons in comparison with age-matched WT mice (lower panel). The area of
connective tissue was significantly increased in KO mice (lower panel). However, these changes were not observed in the KO mice with the
chronic administration of tacrolimus (lower panel). Scale bar=10 μm. C: The numbers of axons were counted from 10 fields of identical size
(18 μm×18 μm). The Bar graph shows a significant decrease at 10 months of age in KO mice compared to parental mice (WT) and the KO
mice treated with tacrolimus (Tac.). Data are the mean±SEM (each 5). Data were analyzed by the Mann–Whitney U-test (**p<0.0001,
*p<0.001). D: Immunohistochemical staining with a-Bax antibody (clone 6A7) or normal mouse serum plus tissue sections from 9-month-
old wild type mice (WT) and p50-deficient (KO) mice with and without chronic administration of tacrolimus. Bax expression was observed
in the GCL of KO mice, but not age-matched KO mice treated with tacrolimus (Tac.) or WT mice. GCL=ganglion cell layer, IPL=inner
plexiform layer. Green; Bax, Red; PI. Original magnification; 100×.
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2166such as in human NTG [35]. On the other hand, p50-deficient
mice  revealed  chronic  spontaneous  optic  neuropathy  with
many features resembling human NTG [25]. Because NF-κB
plays such a crucial role in optic neuropathy as well as the
nervous  system  [36-39],  it  is  important  to  identify  the
signaling pathways leading to its activation in neurons. In our
study, the constitutively active cleaved form of CaN, which
has been reported to lead to apoptosis, was detected in the
retina of p50-deficient mice, and then the IHC experiments
showed that NF-κBp65 spontaneously translocates into the
nucleolus of RGCs of p50-deficient mice (Figure 1B). Bax
expression in the retina was higher in p50-deficient mice than
wild type mice, and activated caspase 3 was observed in p50-
deficient mice (Figure 1C). Examinations using the RGC-5
cell  line  also  demonstrated  that  NF-κBp50  expression
contributed greatly to the prevention of NMDA/glutamate-
induced neurotoxicity and is required to protect the RGCs and
optic nerve from spontaneous optic neuropathy (Figure 3). In
short,  p50  itself  can  form  p50/p50  homodimers,  which
generally function as transcriptional repressors to regulate
p50/p65's role as a transcription factor [27,40] (Appendix 1-
Figure 6). Our studies suggested that the p50 deficiency leads
to  CaN-induced  NF-κBp65  activation  resulting  in
spontaneous RGC death based on recent research findings.
As  the  stimulation  of  glutamate  receptors  results  in
membrane depolarization which opens Ca2+ channels, leading
to a rise in the intracellular Ca2+concentration, Ca2+ could play
an important role in NF-κB activity during optic neuropathy.
NF-κB's activation by various stimuli has already been shown
to  require  Ca2+  for  proper  signal  transduction  [41,42].
However, the exact process involved in transducing the Ca2+
signal  in  optic  neuropathy  remains  to  be  elucidated.  To
address this, we analyzed the neuroprotective effects of a
Ca2+ blocker on RGCs in p50-deficient mice. A protective
effect  of  the  chemical  reagents,  which  act  on  the  Ca2+-
signaling  pathway,  against  spontaneous  optic  nerve
neuropathy was clearly demonstrated based on the chronic
administration of reagents to p50-deficient mice as well as
transient experiments (Figure 2A, Figure 4A).
CaN,  a  ubiquitously  expressed  Ca2+/calmodulin-
dependent  protein  kinase  II  (CaMKII)  -dependent  protein
phosphatase  that  is  a  critical  component  of  several  Ca2+-
dependent  signaling  pathways,  controls  transcriptional
regulation, cell cycle progression, and cell survival. A recent
report demonstrated a marked decrease in the level of NF-κB
constitutive activity when CaN was specifically inhibited, at
both  nuclear  translocation  and  transactivation  levels,
suggesting the central importance of CaN in NF-κB activity
in neurons [43]. Cleaved CaN was detected in the retina of
p50-deficient mice (Figure 1C), and then the protective effect
of  tacrolimus  against  optic  neuropathy  was  elucidated  by
transient experiments as well as chronic administration to
Figure 5. Putative biologic function of NF-κB in spontaneous optic neuropathy in NF-κBp50- deficient mouse. A calcineurin (CaN) signal
cascade involving impaired NF-κB activation induces spontaneous RGC death.
Molecular Vision 2011; 17:2157-2170 <http://www.molvis.org/molvis/v17/a234> © 2011 Molecular Vision
2167p50-deficient  mice  (Figure  2  and  Figure  3).  Even  though
RGC-5 cells were stimulated by glutamate, the pre-treatment
with  tacrolimus  reduced  activated  caspase  3  and  Bax
expression in RGC-5 cells. The amount of Bax in RGCs and
TUNEL-positive RGCs of p50-deficient mice was markedly
decreased by the chronic administration of tacrolimus (Figure
3C and Figure 4D). These research findings suggest that a CaN
signal cascade involving impaired NF-Bactivation induces
spontaneous RGC death (Figure 5).
Several  studies  have  shown  the  potential  role  of  the
immune system, i.e., autoantibodies against ocular antigens,
in the pathogenesis of glaucoma [2]. The p50-deficient mice
exhibited multiple immune response defects [7]. Our previous
data demonstrated the possible production of autoantibodies
in the retinas of p50-deficient mice [25]. Tacrolimus is an
immunosuppressive reagent whose main use is after allogenic
organ transplant to reduce the activity of the patient's immune
system, and so lower the risk of organ rejection. Therefore,
another  possibility  is  that  tacrolimus  inhibits  the  immune
system, especially autoimmunity. To clarify the mechanism
by which tacrolimus promotes RGC survival, further studies
must be performed.
One  important  issue  that  remains  to  be  resolved  in
neuronal  physiology  is  how  a  signal  that  is  released  by
neurotransmitters binding to their receptors at the synapse,
and  is  transduced  into  the  nucleus  to  activate  gene
transcription. Despite the importance of NF-κB to neuronal
function  and  survival,  little  is  known  about  the  signaling
pathways  leading  to  its  activation.  In  this  study,  we
demonstrated that p50 expression is required for optic nerve
cell survival, suggesting a connection between the loss of p50
expression and optic neuropathy. The mechanism whereby
CaN-dependent pathways activate NF-κB is still unknown;
we have chosen to utilize p50-deficient mice as well as RGC-5
cells to investigate the mechanisms by which the CaN signal
cascade stimulates NF-κB-mediated neuronal cell death. The
factors that act on the CaN-dependent pathway might become
targets in the clinical treatment of NTG. Clinical studies have
shown that there is a correlation between NTG and migraine
with aura (MA): significant evidence of alinkage was found
between MA phenotype and the marker D4S1647 on 4q24,
where  the  NF-κBp50-coding  gene  is  located  [44].
Unfortunately,  scientific  evidence  which  directly  shows  a
correlation between defective p50 expression and NTG has
yet to be obtained.
In conclusion, tacrolimus protects RGCs from chronic
spontaneous optic neuropathy, and then a CaN signal cascade
including  NF-κB  activation  induced  chronic  spontaneous
optic neuropathy. Our results provide a new framework for
understanding how cross-talk integrates a variety of signals in
a  physiologic  context  for  the  initiation  of  chronic  optic
neuropathy.  These  findings  provide  strong  additional
information regarding therapeutic targets for NTG.
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